Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.
DTC
Decision tree model
Differentiated thyroid cancer
PT-WBS
Post-treatment whole-body scintigraphy
Tg
Thyroglobulin
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
07
03
2023
accepted:
19
04
2023
medline:
5
7
2023
pubmed:
1
5
2023
entrez:
30
4
2023
Statut:
ppublish
Résumé
An accurate postoperative assessment is pivotal to inform postoperative Age, sex, histology, T stage, N stage, risk classes, remnant estimation, TSH, and Tg were identified as potential predictors and were put into regression algorithm (conditional inference tree, ctree) to develop a risk stratification model for predicting the presence of metastases in PT-WBS. The lymph node (N) stage identified a partition of the population into two subgroups (N-positive vs N-negative). Among N-positive patients, a Tg value > 23.3 ng/mL conferred a 83% probability to have metastatic disease compared to those with lower Tg values. Additionally, N-negative patients were further substratified in three subgroups with different risk rates according to their Tg values. The model remained stable and reproducible in the iterative process of cross validation. We developed a simple and robust decision tree model able to provide reliable informations on the probability of persistent/metastatic DTC after surgery. These information may guide post-surgery
Identifiants
pubmed: 37121981
doi: 10.1007/s00259-023-06239-8
pii: 10.1007/s00259-023-06239-8
pmc: PMC10317893
doi:
Substances chimiques
Thyroglobulin
9010-34-8
Iodine-131
0
Iodine Radioisotopes
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2767-2774Informations de copyright
© 2023. The Author(s).
Références
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461–70.
doi: 10.1089/thy.2018.0597
pubmed: 30900516
Giovanella L. Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. Curr Opin Oncol. 2020;32:7–12.
doi: 10.1097/CCO.0000000000000588
pubmed: 31599768
Knappe L, Giovanella L. Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up. Exp Rev Endocrinol Metab. 2022. https://doi.org/10.1080/17446651.2021.1993060 .
doi: 10.1080/17446651.2021.1993060
Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97:2754–63.
doi: 10.1210/jc.2012-1533
pubmed: 22639291
Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, et al. Application of postsurgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689–98.
pubmed: 20187016
Giovanella L, Ceriani L, Suriano S, Ghelfo A, Mffioli M. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol. 2008;69:659–63.
doi: 10.1111/j.1365-2265.2008.03244.x
Campennì A, Ruggeri RM, Siracusa M, Comis AD, Romano D, Vento A, et al. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur J Nucl Med Molecular Imaging. 2021;48:2466–75.
doi: 10.1007/s00259-020-05153-7
Schneider DF, Ojomo KA, Chen H, Sippel RS. Remnant uptake as a postoperative oncologic quality indicator thyroid. Thyroid. 2013;23:1269–76.
doi: 10.1089/thy.2012.0451
pubmed: 23373869
pmcid: 3783930
Giovanella L. Thyroglobulin-guided (131)I ablation in low-risk differentiated thyroid carcinoma: is the yardstick accurate enough? Head Neck. 2011;33:1379–80.
doi: 10.1002/hed.21788
pubmed: 21739512
Giovanella L, Cosma C, Plebani M. What is the role of serum thyroglobulin measurement in patients with differentiated thyroid cancer treated without radioactive iodine? J Clin Endocrinol Metab. 2017;102:2113–4.
doi: 10.1210/jc.2016-3983
pubmed: 28586450
Giovanella L, Ceriani L, Garo ML. Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis. Clin Chem Lab Med. 2022;60:1091–100.
doi: 10.1515/cclm-2022-0154
pubmed: 35475431
Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014;24:1127–33.
doi: 10.1089/thy.2013.0691
pubmed: 24697314
Görges R, Maniecki M, Jentzen W, N-Yi Sheu S, Mann K, Bockisch A, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153;49–55.
Grebe SK. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Exp Rev Endocrinol Metab. 2009;4:25–43.
doi: 10.1586/17446651.4.1.25
Giovanella L, Duntas LH. Management of endocrine disease: the role of rhTSH in the management of differentiated thyroid cancer: pros and cons. Eur J Endocrinol. 2019;181:133–45.
doi: 10.1530/EJE-19-0149
Giovanella L, Verburg FA. Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement. Thyroid. 2011;21:809–10.
doi: 10.1089/thy.2010.0435
pubmed: 21615306
Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, Van Nostrand D, et al. SNMMI procedure standard/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med. 2022;63:15N-35N.
pubmed: 35649660
Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37:2267–76.
doi: 10.1007/s00259-010-1565-3
pubmed: 20661558
Avram AM, Rosculet N, Esfandiari NH, Gauger PG, Miller BS, Cohen M, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted
doi: 10.1097/RLU.0000000000002321
pubmed: 30371575
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.
doi: 10.1007/s00259-008-0883-1
pubmed: 18670773
Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Elizabeth Lulaj E, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46:2514–25.
doi: 10.1007/s00259-019-04472-8
pubmed: 31392371
Broecker-Preuss M, Mehnert I, Gilman E, Herrmann K, Weber M, Görges R. Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assays. Pract Lab Med. 2921; 21: e00250.
Gulec SA, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Draganescu C, et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid. 2021;31:1009–19.
doi: 10.1089/thy.2020.0826
pubmed: 33789450
Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F, Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin stimulated assay and imaging procedures. Clin Chem Lab Med. 2006;44:648–52.
doi: 10.1515/CCLM.2006.107
pubmed: 16681439
Kowalska A, Pałyga I, Gąsior-Perczak D, Walczyk A, Trybek T, Słuszniak A, Mezyk R, Gozdz S. The cut-off level of recombinant human TSH-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer. PLoS ONE. 2015;10: e0133852.
doi: 10.1371/journal.pone.0133852
pubmed: 26230494
pmcid: 4521804
Gao H, Huang J, Dai Q, Su J. Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer. Arch Endocrinol Metab. 2023;67/2. https://doi.org/10.20945/2359-3997000000538.
Tian T, Qi Y, Huang S, Wang H, Huang R. Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels. J Clin Endocrinol Metab. 2023; dgad045. https://doi.org/10.1210/clinem/dgad045.